Daughter of Fauci’s Replacement Tied to FDA Consulting Firm Advising on COVID-19 Regulations

“The daughter of Hugh Auchincloss – selected to be Anthony Fauci’s temporary successor at the National Institute of Allergy and Infectious Diseases – works for a leading Food and Drug Administration consulting firm advising American pharmaceutical companies,” according to an exclusive report from Natalie Winters.

🚨🚨🚨

EXC: Daughter Of Fauci’s Replacement Is FDA Consultant Advising On COVID-19 Regulations, Vaccine Authorization.https://t.co/pLufSurZCd

— Natalie Winters (@nataliegwinters) December 21, 2022

As if the above stated conflict of interest wasn’t dubious enough, she authored strategy papers for the company focused on COVID-19 regulations.

Natalie Winters provided further details at War Room:

Hugh Auchincloss has been Fauci’s number two at the National Institutes of Health (NIH) agency since 2006, giving him considerable influence over the federal agency’s vaccine policies during the COVID-19 pandemic and push to collaborate more with the Chinese Communist Party on research.

He is also the aide Fauci sent panicked emails to about the gain of function research occurring in Wuhan in the early days of the pandemic. In a recent deposition, Fauci also identified Auchincloss as responsible for reversing a ban on federal funds supporting gain of function research in the case of Ralph Baric – who shared his deadly research tactics with scientists in Wuhan.

The War Room can reveal another conflict of interest held by the Fauci successor, as his daughter, Kalah Auchincloss, is the Executive Vice President and Deputy General Counsel of Greenleaf Health.

Dubbed by the media as the “most influential FDA consulting firm you’ve never heard of,” the company describes itself as “a leading FDA regulatory consulting firm that provides strategic and technical guidance to pharmaceutical, biotechnology, and medical device companies.”

The FDA is the federal agency responsible for the approval of COVID-19 vaccines.

Greenleaf Health’s advisory services appear to intersect with the aforementioned market, as it works on behalf of clients to provide assistance with “drug and biological products.”

“Auchincloss is the father of Rep. Jake Auchincloss (D-Mass.). His daughter, Kalah Auchincloss, an executive vice president at Greenleaf Health..”

Fauci’s Longtime No. 2 Tapped to Head Infectious Disease Center https://t.co/xxaFwJf3DO

— BMF (@Lafcurve) December 11, 2022

Greenleaf Health’s Drug & Biological Products page states:

In the challenging world of biopharmaceutical development, companies need a trusted regulatory partner to help them make timely, informed decisions. Greenleaf’s respected FDA experts provide a vital perspective to clients on the complex process of bringing new therapeutics to market.

Auchincloss is a member of Greenleaf Health’s Product Quality, Manufacturing, and Compliance Team:

15 years of experience on Capitol Hill, in the private sector, and at the FDA, including role as Deputy Chief of Staff.

Her bio on Greenleaf Health shows a lengthy government career, including a stint as FDA Deputy Chief of Staff:

Kalah has 15 years of food and drug legal, policy, and regulatory experience at the FDA, on Capitol Hill, and in the private sector. Kalah spent six years at the FDA, including as Deputy Chief of Staff for two FDA Commissioners, Dr. Robert Califf and Dr. Scott Gottlieb. As Deputy Chief of Staff, Kalah worked with senior FDA leadership to manage crises, develop policy decisions, implement communications strategies, and liaise with the Department of Health and Human Services, the White House, and other agencies. Kalah was also a primary point of contact in the immediate Office of the Commissioner for the six FDA Centers and other components of the Commissioner’s Office.

Prior to that role, Kalah spent time on Capitol Hill as the FDA detailee to the Senate Committee on Health, Education, Labor, and Pensions, working on the 21st Century Cures Act and other FDA-related legislation. She has also served in the FDA’s Center for Drug Evaluation and Research (CDER) as a regulatory counsel in the Office of Regulatory Policy, and as Director of CDER’s Office of Unapproved Drugs and Labeling Compliance in the Office of Compliance, leading a team of more than 50 staff working on pharmacy compounding, unapproved drugs, over-the-counter drugs, and other enforcement issues.